Spirochetes antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Spirochetes antibodies pairs and antigen for animal health (animal Swine/Porcine/Pig infectious disease dysentery) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Swine/Porcine/Pig disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P096-Ag01	Recombinant Spirochetes protein	$3090.00
GMP-VT-P096-Ab01	Anti-Spirochetes mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P096-Ab02	Anti-Spirochetes mouse monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P096-Ag01
Product Name	Recombinant Spirochetes protein
Pathogen	Spirochetes
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Spirochetes antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Spirochetes level test of animal Swine/Porcine/Pig infectious disease with dysentery.
Tag	His
Product description	Recombinant Spirochetes proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P096-Ab01,GMP-VT-P096-Ab02
Pathogen	Spirochetes
Product Name	Anti-Spirochetes mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Spirochetes antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Spirochetes antibodies in Spirochetes level test of animal Swine/Porcine/Pig infectious disease with dysentery.
Product description	Anti-Spirochetes mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Spirochetes antibodies./td>
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen

At that time, the world was undergoing significant changes, both socially and technologically. The ongoing COVID-19 pandemic had already transformed various aspects of our daily lives, prompting widespread adoption of remote work, online education, and digital communication tools. Despite the challenges posed by the pandemic, scientific communities and pharmaceutical companies were actively engaged in developing vaccines to combat the virus. The emergence of several effective vaccines, such as those developed by Pfizer-BioNTech, Moderna, and AstraZeneca, offered hope for controlling the spread of the virus and returning to a semblance of normalcy.

In terms of technological advancements, artificial intelligence and machine learning were rapidly evolving fields, with applications across various industries, including healthcare, finance, and customer service. Companies were increasingly investing in AI-driven solutions to streamline their operations, enhance customer experiences, and gain valuable insights from data analysis. Additionally, the rise of automation and robotics was reshaping the job market, leading to discussions about the potential impact on employment and the need for upskilling and reskilling programs.

The field of renewable energy was also experiencing significant growth, driven by a global push for sustainability and reduced carbon emissions. Solar and wind power, in particular, were becoming increasingly cost-effective and accessible, leading to their widespread adoption in many regions. Governments and organizations were implementing policies and initiatives to encourage the transition to clean energy sources and combat climate change.

Furthermore, the realm of space exploration and technology was witnessing notable advancements. Private companies such as SpaceX, Blue Origin, and Virgin Galactic were actively involved in developing reusable rocket technology and aiming to make space travel more accessible to the public. Meanwhile, international space agencies were collaborating on missions to explore Mars, the Moon, and other celestial bodies, seeking to expand our understanding of the universe and the potential for human colonization beyond Earth.

These developments, along with numerous other ongoing global trends, were shaping the world in 2021, emphasizing the importance of innovation, sustainability, and adaptability in navigating the challenges and opportunities of the modern era.

About GDU